2 recruiting. 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Recruiting 2 |
Follow SciTech Development, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer Fenretinide - Small Cell Lung Cancer | Phase 1 | Recruiting | SciTech Development, Inc. | 44 | 2025-12-11 | 2026-08-19 |
| Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma Fenretinide - T-cell Lymphoma, Cutaneous/Peripheral T-Cell Lymphoma | Phase 1 | Recruiting | SciTech Development, Inc. | 46 | 2023-12-18 | 2026-10-05 |
Immunoblastic Lymphadenopathy (1) · Lymphoma (1) · Lymphoma, T-Cell (1) · Lymphoma, T-Cell, Cutaneous (1) · Lymphoma, T-Cell, Peripheral (1) · Mycosis Fungoides (1) · Recurrence (1) · Sezary Syndrome (1) · Small Cell Lung Carcinoma (1)
Fenretinide (2) · MAC-ST-001 (2)
United States (2)
Ali Moiin, MD (2) · Aaron R Mangold, M.D. (1) · Ann F Mohrbacher, MD (1) · Auris O Huen, MD, PharmD (1) · Barbara Pro, MD (1) · Brad Haverkos, M.D. (1) · Christiane Querfeld, M.D., Ph.D. (1) · Dipenkumar Modi, MD (1) · Jonathan Moreira, M.D. (1) · Oleg E Akilov, MD, PhD (1) · Ryan A Wilcox, MD, PhD (1)